DelveInsight's "Molluscum Contagiosum Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Molluscum Contagiosum (MC), historical and forecasted epidemiology as well as the Molluscum Contagiosum market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Molluscum Contagiosum market report provides current treatment practices, emerging drugs, Molluscum Contagiosum market share of the individual therapies, current and forecasted Molluscum Contagiosum market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Molluscum Contagiosum (MC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Molluscum Contagiosum market.
Molluscum Contagiosum: An Overview
Molluscum contagiosum (MC) is a common skin condition, caused by a member of the poxvirus (molluscum contagiosum virus) family that causes considerable parental anxiety and results in primary and secondary care consultations. It is a mild skin disease characterized by lesions that may appear anywhere on the body consisting of single or, more often, multiple, rounded, dome-shaped, pink, waxy papules that are 2–5 mm in diameter. People with weakened immune systems are at higher risk for getting MC.
Discover more related information of the report- https://www.delveinsight.com/report-store/molluscum-contagiosum-mc-market
Key highlights of the Molluscum Contagiosum Market Report
· A paper titled as "Molluscum contagiosum virus MC159 abrogates cIAP1-NEMO interactions and inhibits NEMO polyubiquitination" by Sunetra et al. (2017), stated that MC infections are common worldwide and approximately 122 million cases were occur in 2010.
· According to another study titled “The epidemiology of molluscum contagiosum in children” by Eichenfield et al. (2005) result showed that the occurrence of MC lesions was common in trunk anatomic location in comparison of Extremities and face in the United States.
· According to the study conducted in UK titled “Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study” by Francis et al. (2015) stated that Molluscum contagiosum has the greatest incidence in individuals aged 1–14 years.
Molluscum Contagiosum Market Outlook
Molluscum contagiosum (MC) is a common skin condition that primarily affects children, a common reason for presenting in primary care and is commonly seen in children presenting with other conditions in primary and secondary care. It is usually asymptomatic but can present with pain, pruritus, erythema and bacterial superinfection. The Molluscum contagiosum treatmen for healthy individualsis unnecessary because Molluscum contagiosum is self-limited in healthy individuals. The treatment is mainly recommended if the lesions are in the genital area (on or near the penis, vulva, vagina, or anus) or in the location of the face and neck. Although there is no FDA-approved topical therapy is present to date for the treatment of MC. The treatment is mainly dependent on the Physical removal of lesions, Oral therapy, and off-label topical therapy.
There are a number of topical treatments like creams, lotions, and ointments that can be used to treat MC, although there's not enough evidence to know if any particular treatment is more effective than the others. Some of the off-label therapies include Potassium hydroxide, Podophyllotoxin, Imiquimod, Benzoyl peroxide, Tretinoin, and others.
Molluscum Contagiosum Emerging Therapy Analysis
Several emerging therapies for the treatment of Molluscum contagiosum (MC) are in different stages of clinical development. Some of the key players involved in the development of therapies for MC are Ligand Pharmaceuticals, Novan, Verrica Pharmaceuticals, Veloce BioPharma, and others are currently working towards the development of the management of the MC. The agents that are under development by these companies include SB206 (Ligand Pharmaceuticals/ Novan), VP-102 (Verrica Pharmaceuticals), and others.
Molluscum Contagiosum Market Report Scope
· The report covers the descriptive overview of Molluscum Contagiosum (MC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
· Comprehensive insight has been provided into the Molluscum Contagiosum (MC) epidemiology and treatment in the 7MM
· Additionally, an all-inclusive account of both the current and emerging therapies for Molluscum Contagiosum (MC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
· A detailed review of the Molluscum Contagiosum market; historical and forecasted is included in the report, covering drug outreach in the 7MM
· The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Molluscum Contagiosum market
Molluscum Contagiosum Market Report Highlights
· In the coming years, the Molluscum Contagiosum market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
· The companies and academics are working to assess challenges and seek opportunities that could influence Molluscum Contagiosum (MC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
· Major players are involved in developing therapies for Molluscum Contagiosum (MC). The launch of emerging therapies will significantly impact the Molluscum Contagiosum market
· A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Molluscum Contagiosum (MC)
· Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Related Topics
Recent Pharmaceuticals Research Reports by Delveinsight
- Technical Due Diligence Firms
- Facial Lines Market
- Adult T-Cell Leukemia-Lymphoma Market
- Shingles Market
- Kaposi’s Sarcoma Market
- Surgical Mask & Respirator Market
- Plaque Modification Devices Market
- Stem Cell Market
- Inflammatory Pain Market
- Hepatic Cirrhosis Market
- Sly Syndrome Market
- Shigellosis Market
- Tuberculosis Market
- Asperger Syndrome Market
- B-Cell Maturation Antigen Targeted Therapies Market
- Oncolytic Virus Cancer Therapy Pipeline
- Sick Sinus Syndrome Market
- Urinary Catheters Market
- Medical Marijuana Market
- B Cell Chronic Lymphocytic Leukemia Market
Trending & Popular Research Reports by Delveinsight
